Outcomes in Healthcare: the supplier/pharma perspective
The pharmaceutical industry is one of the largest suppliers of healthcare systems and solutions. A global industry, its core business is discovering, developing and selling commercialized drugs. However, drugs are only one part of treatment and there is recognition within companies of a need for change including:
Discussing outcomes at every stage of the product lifecycle from drug discovery to patent expiry.
Stopping programs early which cannot demonstrate positive outcomes for patients.
Reconfiguring workforces to improve efficiency and add value.
Old ways of working persist
For many companies, the operating model is still focused on a business model of revenue generated by selling drugs. Huge inertia also acts as a barrier to creating variability. To overcome these obstacles, pharma needs a new way of working for the 21st Century which is:
Reform means no longer inventing concepts which last a couple of years but delivering improved care so the patient is on a better overall treatment and follow-up regimen.
Delivering innovation through the treatment pathway
Innovation needs to be at the heart of the entire treatment pathway, and not just in delivering a new molecule. It also means partnering with the healthcare sector to understand patient pathways and flows, identifying efficiencies, adapting to stakeholder needs with solutions that combine with the product to improve outcomes for patients.
Change will also require a major shift in approach by introducing new capabilities - even a new workforce. In addition, it means embedding outcome in a company’s strategy so the focus is patient-centered and embrace solution development through disease management programs.
MSD and Janssen are among those major pharmaceutical industry suppliers placing outcomes at the center of their core strategies. Aspire is Janssen’s strategic roadmap for change aimed at: generating better outcome for patients, regaining credibility and trust, and adapting the operating model to fulfill the first two goals.
MSD’s new approach towards treatment pathways is Evidence into Practice (EiP), a structured clinical management program aimed at ensuring people receive optimal care for long-term conditions such as diabetes.
Content from Gensearch Whitepaper “Life Science Talks”